GSK and Theravance set sights on early LABA/LAMA combo filing
This article was originally published in Scrip
Executive Summary
Top-line data from four 24-week studies of GlaxoSmithKline and Theravance's LABA/LAMA combination are positive enough to warrant slightly earlier than planned global filings for regulatory approval for the treatment of chronic obstructive pulmonary disease (COPD) starting at the end of this year, the companies say. The markets responded mildly but positively to the news, with GSK's share price rising 1.7%, adding around £1.23 billion ($1.93 billion) to the company's market valuation.
You may also be interested in...
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors
The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.